TargetMol

MHY884

Product Code:
 
TAR-T25807
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T25807-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25807-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25807-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
MHY884 is an inhibitor of tyrosinase that acts by inhibiting UVB-induced activation of the NF-κB signaling pathway through the downregulation of oxidative stress.
CAS:
1393371-35-1
Formula:
C15H14ClNO3S
Molecular Weight:
323.79
Purity:
0.98
SMILES:
COc1cc(cc(OC)c1O)C1Nc2cc(Cl)ccc2S1

References

1. Choi YJ, Uehara Y, Park JY,et al. MHY884, a newly synthesized tyrosinase inhibitor, suppresses UVB-induced activation of NF-?B signaling pathway through the downregulation of oxidative stress. Bioorg Med Chem Lett. 2014 Mar 1;24(5):1344-8. doi: 10.1016/j.bmcl.2014.01.040. Epub 2014 Jan 25. PubMed PMID: 24508132. 2. Ha YM, Uehara Y, Park D, Jeong HO, Park JY, Park YJ, Lee JY, Lee HJ, Song YM, Moon HR, Chung HY. Synthesis and preliminary in vitro biological evaluation of 5-chloro-2-(substituted phenyl)benzo[d]thiazole derivatives designed as novel antimelanogenesis agents. Appl Biochem Biotechnol. 2012 Nov;168(6):1416-33.